Chemotherapy and immunotherapy using monoclonal antibodies have been relatively ineffective for the treatment of brain tumors, in part because of the blood-brain barrier (BBB). Enhanced dose intensity may be achieved by using osmotic BBB disruption (BBBD). During the current funding period, we have reported a multi-institutional series of 174 patients with primary central nervous system lymphoma (PCNSL) treated up front with methotrexate based chemotherapy and BBBD, with a 40% progression free survival at 5 years. This is among the best reported survival for PCNSL in the scientific literature. Improved survival appears to have been achieved without cognitive loss. In the current proposal we hope to improve these results using antibody based therapy in the two compartment model focusing on PCNSL for proof of principle;and to begin extending these concepts to the increasing problem of CNS breast cancer metastasis.
In Aim 1, Mechanisms to improve brain tumor models, we will optimize hematogenous and intracerebrally implanted rat models of human brain tumors.
In Aim 2, Characterization of immunotherapy treatment approaches and neurotoxicity in brain tumor models, the effect of immunotherapy, drug- and radio-immunoconjugates, and combination therapies will be assessed in a new rat intracerebral model of CNS lymphoma (CNSL) and in breast cancer brain metastases models.
In aim 3 we will test whether treatment with the anti-VEGF mAb bevacizumab will prevent vascularization and tumor growth in micrometastatic brain tumors, as a mechanism to approach brain tumor prophylaxis.
In aim 4 clinical trials of immunotherapy, radioimmunotherapy, and neurotoxicity in PCNSL will be conducted. Phase I and II clinical trials will investigate the safety and efficacy of rituximab with chemotherapy after BBBD in newly diagnosed and recurrent PCNSL, and radioimmunotherapy with yttrium-90 labeled anti- CD20 mAb ibritumomab tiuxetan (Zevalin""""""""). We also will characterize neurotoxicity in PCNSL patients who have survived 2+ years in complete response after chemotherapy +/- radiotherapy. In this renewal, we hope to continue to target the BBB using antibodies in a rare primary brain tumor to increase survival and decrease neurotoxicity by avoiding whole brain radiation;and to begin to translate this to CNS breast cancer metastasis, an increasingly common CNS malignancy. This proposal is in response to the Brain Tumor PRG sponsored by NINDS and NCI.

Public Health Relevance

Characterize mechanisms to improve brain tumor models. Evaluate immunotherapy delivery and efficacy, and assess drug immunoconjugates, radioimmunoconjugates, and vascular targeting agents in preclinical brain tumor models. Perform clinical trials of antibody-based therapy and neurotoxicity in human primary central nervous system lymphoma.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project (R01)
Project #
Application #
Study Section
Brain Injury and Neurovascular Pathologies Study Section (BINP)
Program Officer
Timmer, William C
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Oregon Health and Science University
Schools of Medicine
United States
Zip Code
Wu, Yingjen Jeffrey; Pagel, Michael A; Muldoon, Leslie L et al. (2017) High ?v Integrin Level of Cancer Cells Is Associated with Development of Brain Metastasis in Athymic Rats. Anticancer Res 37:4029-4040
Ambady, Prakash; Fu, Rongwei; Netto, Joao Prola et al. (2017) Patterns of relapse in primary central nervous system lymphoma: inferences regarding the role of the neuro-vascular unit and monoclonal antibodies in treating occult CNS disease. Fluids Barriers CNS 14:16
Horváth, Andrea; Varallyay, Csanad G; Schwartz, Daniel et al. (2017) Quantitative comparison of delayed ferumoxytol T1 enhancement with immediate gadoteridol enhancement in high grade gliomas. Magn Reson Med :
Ambady, P; Wu, Y J; Walker, J M et al. (2017) Enhancing the cytotoxicity of chemoradiation with radiation-guided delivery of anti-MGMT morpholino oligonucleotides in non-methylated solid tumors. Cancer Gene Ther 24:348-357
Toth, Gerda B; Varallyay, Csanad G; Horvath, Andrea et al. (2017) Current and potential imaging applications of ferumoxytol for magnetic resonance imaging. Kidney Int 92:47-66
McConnell, Heather L; Kersch, Cymon N; Woltjer, Randall L et al. (2017) The Translational Significance of the Neurovascular Unit. J Biol Chem 292:762-770
Varallyay, C G; Toth, G B; Fu, R et al. (2017) What Does the Boxed Warning Tell Us? Safe Practice of Using Ferumoxytol as an MRI Contrast Agent. AJNR Am J Neuroradiol 38:1297-1302
Dósa, Edit; Heltai, Krisztina; Radovits, Tamás et al. (2017) Dose escalation study of intravenous and intra-arterial N-acetylcysteine for the prevention of oto- and nephrotoxicity of cisplatin with a contrast-induced nephropathy model in patients with renal insufficiency. Fluids Barriers CNS 14:26
Muldoon, Leslie L; Pagel, Michael A; Netto, Joao Prola et al. (2016) Intra-arterial administration improves temozolomide delivery and efficacy in a model of intracerebral metastasis, but has unexpected brain toxicity. J Neurooncol 126:447-54
Netto, Joao Prola; Schwartz, Daniel; Varallyay, Csanad et al. (2016) Misleading early blood volume changes obtained using ferumoxytol-based magnetic resonance imaging perfusion in high grade glial neoplasms treated with bevacizumab. Fluids Barriers CNS 13:23

Showing the most recent 10 out of 44 publications